On February 3, 2020, Aevi Genomic Medicine, Inc. ("Aevi") consummated a two-step merger (the "Merger") with Cerecor Inc. ("Cerecor"), in accordance with the terms of the previously disclosed Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2019, by and between Aevi, Cerecor, Genie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Cerecor ("Merger Sub") and Second Genie Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of Cerecor ("Second Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into Aevi, with Aevi as the surviving corporation, and as part of the same overall transaction, Aevi then merged with and into Second Merger Sub, with Second Merger Sub as the surviving entity. The surviving entity from the second merger was renamed Aevi Genomic Medicine, LLC (the "Surviving Entity"). As a result of the Merger and pursuant to letters of resignation, at the effective time of the Merger, the following persons ceased to be directors of Aevi: Sol J. Barer, Eugene A. Bauer, Matthew Bayley, Alastair Clemow, Michael F. Cola, Barbara Duncan and Joseph J. Grano, Jr. None of these resignations were a result of any disagreement with Aevi, its management or the board of directors. As a result of the Merger and pursuant to letters of resignation, at the effective time of the Merger, the following individuals ceased to be officers of Aevi: Michael F. Cola, Michael H. McInaw and Garry Neil. None of these resignations were a result of any disagreement with Aevi, its management or the board of directors.